ChristosArgyropoulos (@ChristosArgyrop )

ChristosArgyropoulos

Bio Division Chief, Nephrology @UNMHSC
Tweets: med, pharma, stats, econ, policy, HPC linkedin.com/in/chrisarg
Dont infer endorsement from RT/Likes

Location Land of Enchantment
Tweets 53,6K
Followers 5,2K
Following 2,9K
Account created 18-09-2011 19:18:19
ID 375801620

Twitter Web App : Spain is well into its 2nd wave, with recent daily case numbers already ~1/2 of what they were at the peak in late March. 🦠🇪🇸🔥

Twitter Web App : Multiple studies of a given medication shows substantial and (statistically significant) improvements in hard clinical outcomes. Should you even bother with the effects on intermediate biomarkers before prescribing the drug to actual patients?

Twitter Web App : Raj Mehta, MD The equipoise is ultimately up to individual MDs & the research question e.g. I haven't felt that equipoise exists for SGLT2is in diabetic CKD since 2016 & would never randomize a patient with DM2 and CKD to SGLT2i, yet I'd feel comfy randomizing a non DM2 pt to SGLT2i